REGN

Regeneron Pharmaceuticals Stock (NASDAQ: REGN)

Dernières nouvelles pour Regeneron Pharmaceuticals (NASDAQ:REGN) Stock

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).

Regeneron Pharmaceuticals, Inc. - Common Stock

Regeneron Pharmaceuticals Inc

REGENERON PHARMACEUTICALS ORD

Regnum Corp

The stock market&#39;s impressive and resilient performance in 2024, with the SPDR S&amp;P 500 ETF&nbsp;up over 21% YTD and trading at all-time highs, has led many investors to chase high-flying stocks at all-time highs. However, this approach can be risky as stocks stretched to the upside might face corrections. Instead, focusing on oversold stocks that offer solid risk-to-reward ratios may be more rewarding.&nbsp;
Identifying oversold stocks can be done using several strategies: valuation metrics like P/E ratios, technical indicators like RSI (with a reading below 40 suggesting oversold conditions), or analyzing a stock&#39;s price action around crucial support levels within a broader uptrend.
Here&#39;s a look at three stocks that appear oversold and may present attractive buying opportunities.
<h2>Micron Retraces Following Earnings Beat</h2>
Micron Technology, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mu#NASDAQ">MU</a>), a significant player in the semiconductor industry, recently posted a strong earnings beat on September 25th, but shares have since pulled back. After surging to $114.8 following the earnings report, the stock has retraced to $101.7. Despite this pullback, the stock has found support and looks ready to continue its upward trend, presenting an attractive risk-reward opportunity for investors.
In its latest earnings report, Micron posted an EPS of $1.18, beating estimates by $0.21, with revenue of $7.75 billion, up 93.3% year-over-year. This impressive growth signals Micron&#39;s ability to capitalize on the strong semiconductor demand, particularly in artificial intelligence and data centers. Analysts are bullish on the stock, with a Moderate Buy consensus based on 27 ratings, 25 of which are Buy recommendations. The consensus price target of $142.85 represents a potential 40.5% upside, making Micron an enticing pick.
Additionally, with its RSI nearing 40, Micron is approaching oversold territory. Combined with solid fundamentals and analyst optimism, this indicates that the current pullback may be a compelling entry point for long-term investors looking for a potential recovery play in the semiconductor sector.
<h2>Biogen Nears Oversold and Undervalued Territory</h2>
Biogen Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/biib#NASDAQ">BIIB</a>), a prominent player in the biotechnology space, has had a challenging year, with its stock down nearly 30% YTD. However, this significant decline has left the stock in both oversold and undervalued territory. Currently trading with an RSI of 36, it might be nearing a potential rebound point. The stock&#39;s P/E ratio of 23.4 and forward P/E of 10.82 also suggest a valuation that could attract long-term investors.
Biogen reported strong Q2 results, posting an EPS of $5.28, which beat expectations by $1.28, on revenue of $2.47 billion. While revenue growth was modest at 0.4% year-over-year, the stock&#39;s potential upside is catching analysts&#39; attention. Biogen holds a Moderate Buy rating, with analysts forecasting a 47% upside, making it a prime candidate for investors looking to capitalize on a turnaround.
Beyond technical indicators, institutional inflows into the stock further underscore the interest in Biogen as a potential recovery play. Over the past twelve months, inflows have reached $3.57 billion, compared to $2.24 billion in outflows, signaling confidence among institutional investors that the stock&#39;s current valuation might be an attractive entry point.
<h2>REGN Finds Support Near Its 200-day SMA</h2>
Regeneron Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/regn#NASDAQ">REGN</a>), another biotech heavyweight, has pulled back into a critical support level at its rising 200-day simple moving average (SMA), currently near $1,000. The last time the stock hit this major moving average, it surged from $900 to nearly $1,200 within four months. With the stock now trading just above $1,000, history could be about to repeat itself.
Regeneron&#39;s Q2 earnings beat estimates by a wide margin, with EPS of $11.56 surpassing estimates by $2.63 and revenue of $3.55 billion, a 12.3% year-over-year increase. The stock&#39;s RSI is now hovering around 30, signaling oversold conditions. With earnings set to be released on October 31, a positive report could propel Regeneron back upward. Analysts are optimistic, with a consensus price target indicating more than 10% upside potential.
Regeneron&#39;s impressive historical performance, robust financials, and strong earnings potential make it a stock to watch as it approaches critical technical support levels. The stock could be poised for a sharp recovery if the company delivers another earnings beat in its upcoming report.
The article &quot;<a href="https://www.marketbeat.com/stock-ideas/these-3-stocks-are-screaming-oversold-seize-the-opportunity/">These 3 Stocks Are Screaming Oversold: Seize the Opportunity</a>&quot; first appeared on MarketBeat.

Biotech

Earnings

Earnings Beats

Large Cap

News

Sector ETFs

Price Target

Markets

Analyst Ratings

Tech

Trading Ideas

ETFs

General

BIIB

These 3 Stocks Are Screaming Oversold: Seize the Opportunity

Regeneron Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) has outperformed the market over the past 15 years by 18.57% on an annualized basis producing an average annual return of 30.32%. Currently, Regeneron Pharmaceuticals has a market capitalization of $110.13 billion. 
Buying $100 In REGN: If an investor had bought $100 of REGN stock 15 years ago, it would be worth $5,227.73 today based on a price of $999.02 for REGN at the time of writing.
<h3>Regeneron Pharmaceuticals's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1728594009_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $100 Invested In Regeneron Pharmaceuticals 15 Years Ago Would Be Worth Today

Whales with a lot of money to spend have taken a noticeably bullish stance on Regeneron Pharmaceuticals.
Looking at options history for Regeneron Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) we detected 9 trades.
If we consider the specifics of each trade, it is accurate to state that 66% of the investors opened trades with bullish expectations and 22% with bearish.
From the overall spotted trades, 3 are puts, for a total amount of $152,500 and 6, calls, for a total amount of $296,619.
<h3>Projected Price Targets</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $520.0 to $1090.0 for Regeneron Pharmaceuticals during the past quarter. 
<h3>Volume &amp; Open Interest Trends</h3>
In terms of liquidity and interest, the mean open interest for Regeneron Pharmaceuticals options trades today is 77.14 with a total volume of 57.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Regeneron Pharmaceuticals's big money trades within a strike price range of $520.0 to $1090.0 over the last 30 days.
<h3>Regeneron Pharmaceuticals 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1728584280_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th style="text-align: right;">Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>REGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/11/24</td>
<td>$90.7</td>
<td>$85.8</td>
<td>$90.8</td>
<td>$1090.00</td>
<td>$90.8K</td>
<td style="text-align: right;">11</td>
<td style="text-align: right;">10</td>
</tr>
<tr>
<td>REGN</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>10/11/24</td>
<td>$198.0</td>
<td>$188.1</td>
<td>$193.97</td>
<td>$820.00</td>
<td>$77.5K</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>REGN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$527.0</td>
<td>$517.0</td>
<td>$527.0</td>
<td>$520.00</td>
<td>$52.7K</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td>REGN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$52.0</td>
<td>$50.1</td>
<td>$52.0</td>
<td>$1040.00</td>
<td>$52.0K</td>
<td style="text-align: right;">286</td>
<td style="text-align: right;">10</td>
</tr>
<tr>
<td>REGN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$51.5</td>
<td>$48.4</td>
<td>$51.5</td>
<td>$1040.00</td>
<td>$51.5K</td>
<td style="text-align: right;">286</td>
<td style="text-align: right;">20</td>
</tr>
</tbody>
</table>

<h3>About Regeneron Pharmaceuticals</h3>
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).
<h3>Where Is Regeneron Pharmaceuticals Standing Right Now?</h3>
<ul>
<li>With a trading volume of 270,067, the price of REGN is down by -1.11%, reaching $1000.96.</li>
<li>Current RSI values indicate that the stock is may be oversold.</li>
<li>Next earnings report is scheduled for 21 days from now.</li>
</ul>
<h3>What Analysts Are Saying About Regeneron Pharmaceuticals</h3>
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $1170.4.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; In a cautious move, an analyst from Truist Securities downgraded its rating to Buy, setting a price target of $1200. 
&#x2A; Reflecting concerns, an analyst from BMO Capital lowers its rating to Outperform with a new price target of $1300. 
&#x2A; An analyst from Cantor Fitzgerald has revised its rating downward to Neutral, adjusting the price target to $1015. 
&#x2A; An analyst from RBC Capital has decided to maintain their Outperform rating on Regeneron Pharmaceuticals, which currently sits at a price target of $1260. 
&#x2A; An analyst from Leerink Partners has revised its rating downward to Market Perform, adjusting the price target to $1077. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Regeneron Pharmaceuticals, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Options

What the Options Market Tells Us About Regeneron Pharmaceuticals

The U.S. Department of Health and Human Services (HHS), through the Centers for Medicare &amp; Medicaid Services (CMS), has released a Request for Information (RFI) regarding a new initiative to lower prescription drug costs for Medicare recipients.
The Medicare $2 Drug List Model, developed under President Biden&#8217;s Executive Order 14087, seeks to offer certain generic drugs for a fixed copayment of no more than $2 per month.
This initiative targets commonly prescribed drugs for conditions like high cholesterol and high blood pressure.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40534249/novo-nordisks-ozempic-might-be-among-2027-medicare-price-negotiation-targets" rel="noreferrer noopener">Novo Nordisk&#8217;s Ozempic Might Be Among 2027 Medicare Price Negotiation Targets</a>.
The Center for Medicare and Medicaid Innovation (Innovation Center) has designed the Medicare $2 Drug List Model to test whether simplifying access to affordable, clinically important generics will improve health outcomes, improve medication adherence, and boost overall satisfaction with the Medicare Part D program.
These drugs, which would not be subject to typical utilization management requirements, could be available at all participating pharmacies as early as January 2027.
The initial list of <a target="_blank" href="https://www.cms.gov/newsroom/press-releases/biden-harris-administration-takes-next-step-proposed-model-lower-prescription-drug-costs-people" rel="noreferrer noopener">drugs</a> for the $2 Drug List Model has been carefully developed through a rigorous process. It incorporates input from physicians, pharmacists, and health policy experts to ensure that the selected medications address common conditions for Medicare recipients.
The concept of a fixed-cost drug list is not new, with many retail pharmacies already offering generic medications at low, standardized prices.
However, the Medicare $2 Drug List Model will be tailored specifically to Medicare recipients.
Last week,&nbsp;the HHS released final guidance for the second &nbsp;Medicare Drug Price <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">Negotiation Program cycle</a>.
This initiative&nbsp;<a target="_blank" href="https://www.cms.gov/newsroom/press-releases/hhs-releases-final-guidance-second-cycle-historic-medicare-drug-price-negotiation-program" rel="noreferrer noopener">aims</a> to provide lower drug prices starting in 2026 and 2027.
The first round of negotiations focused on ten specific drugs. When the new prices take effect in 2026, Medicare recipients should save approximately $1.5 billion in <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41166018/medicare-drug-price-negotiation-program-gets-final-guidance-for-second-cycle-1-5b-savings-expecte" rel="noreferrer noopener">out-of-pocket costs</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41256266/is-the-iphone-losing-its-buzz-among-teens-piper-sandler-finds-out" target="_blank" rel="noreferrer noopener">Is The iPhone Losing Its Buzz Among Teens? Piper Sandler Finds Out</a></li>
</ul>
Image via Shutterstock

Government

Health Care

AMGN

BMRN

GILD

VRTX

Biden Administration Unveils Plan To Provide Generic Drugs for $2 to Medicare Recipients

Amidst today's fast-paced and highly competitive business environment, it is crucial for investors and industry enthusiasts to conduct comprehensive company evaluations. In this article, we will delve into an extensive industry comparison, evaluating Regeneron Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) in comparison to its major competitors within the Biotechnology industry. By analyzing critical financial metrics, market position, and growth potential, our objective is to provide valuable insights for investors and offer a deeper understanding of company's performance in the industry.
<h3>Regeneron Pharmaceuticals Background</h3>
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).
<table>
<thead>
<tr>
<th>Company</th>
<th>P/E</th>
<th>P/B</th>
<th>P/S</th>
<th>ROE</th>
<th>EBITDA (in billions)</th>
<th>Gross Profit (in billions)</th>
<th>Revenue Growth</th>
</tr>
</thead>
<tbody>
<tr>
<td>Regeneron Pharmaceuticals Inc</td>
<td>26.62</td>
<td>3.93</td>
<td>8.53</td>
<td>5.19%</td>
<td>$1.76</td>
<td>$3.07</td>
<td>12.32%</td>
</tr>
<tr>
<td>AbbVie Inc</td>
<td>64.55</td>
<td>50.30</td>
<td>6.22</td>
<td>18.4%</td>
<td>$5.0</td>
<td>$10.26</td>
<td>4.31%</td>
</tr>
<tr>
<td>Amgen Inc</td>
<td>54.77</td>
<td>28.81</td>
<td>5.55</td>
<td>13.63%</td>
<td>$3.0</td>
<td>$5.15</td>
<td>20.07%</td>
</tr>
<tr>
<td>Gilead Sciences Inc</td>
<td>103.91</td>
<td>5.80</td>
<td>3.84</td>
<td>9.01%</td>
<td>$2.98</td>
<td>$5.41</td>
<td>5.36%</td>
</tr>
<tr>
<td>Biogen Inc</td>
<td>22.99</td>
<td>1.67</td>
<td>2.75</td>
<td>3.75%</td>
<td>$0.92</td>
<td>$1.92</td>
<td>0.36%</td>
</tr>
<tr>
<td>United Therapeutics Corp</td>
<td>16.35</td>
<td>2.78</td>
<td>6.69</td>
<td>5.04%</td>
<td>$0.39</td>
<td>$0.64</td>
<td>19.85%</td>
</tr>
<tr>
<td>Genmab AS</td>
<td>18.97</td>
<td>3.28</td>
<td>5.53</td>
<td>4.44%</td>
<td>$2.15</td>
<td>$5.21</td>
<td>29.58%</td>
</tr>
<tr>
<td>Biomarin Pharmaceutical Inc</td>
<td>52.04</td>
<td>2.47</td>
<td>5.16</td>
<td>2.07%</td>
<td>$0.16</td>
<td>$0.58</td>
<td>19.61%</td>
</tr>
<tr>
<td>Incyte Corp</td>
<td>160.34</td>
<td>4.22</td>
<td>3.81</td>
<td>-10.6%</td>
<td>$-0.37</td>
<td>$0.97</td>
<td>9.34%</td>
</tr>
<tr>
<td>Sarepta Therapeutics Inc</td>
<td>159.61</td>
<td>10.60</td>
<td>7.77</td>
<td>0.63%</td>
<td>$0.03</td>
<td>$0.32</td>
<td>38.93%</td>
</tr>
<tr>
<td>Neurocrine Biosciences Inc</td>
<td>33.63</td>
<td>4.49</td>
<td>5.41</td>
<td>2.66%</td>
<td>$0.16</td>
<td>$0.58</td>
<td>30.37%</td>
</tr>
<tr>
<td>Roivant Sciences Ltd</td>
<td>1.97</td>
<td>1.53</td>
<td>59.56</td>
<td>1.67%</td>
<td>$0.09</td>
<td>$0.05</td>
<td>154.96%</td>
</tr>
<tr>
<td>Average</td>
<td>62.65</td>
<td>10.54</td>
<td>10.21</td>
<td>4.61%</td>
<td>$1.32</td>
<td>$2.83</td>
<td>30.25%</td>
</tr>
</tbody>
</table>
<style>
 table {
 width: 100%;
 border-collapse: collapse;
 font-family: Arial, sans-serif;
 font-size: 14px;
 }

 th, td {
 padding: 8px;
 text-align: left;
 }

 th {
 background-color: #293a5a;
 color: #fff;
 text-align: left;
 }

 tr:nth-child(even) {
 background-color: #f2f4f8;
 }

 tr:hover {
 background-color: #e1e4ea;
 }

 td:nth-child(3), td:nth-child(5) {
 text-align: left;
 }

 .dividend-amount {
 font-weight: bold;
 color: #0d6efd;
 }

 .dividend-frequency {
 font-size: 12px;
 color: #6c757d;
 }
 </style>Through a thorough examination of Regeneron Pharmaceuticals, we can discern the following trends: 
<ul>
<li>
The stock's Price to Earnings ratio of 26.62 is lower than the industry average by 0.42x, suggesting potential value in the eyes of market participants.
</li>
<li>
Considering a Price to Book ratio of 3.93, which is well below the industry average by 0.37x, the stock may be undervalued based on its book value compared to its peers.
</li>
<li>
With a relatively low Price to Sales ratio of 8.53, which is 0.84x the industry average, the stock might be considered undervalued based on sales performance.
</li>
<li>
The Return on Equity (ROE) of 5.19% is 0.58% above the industry average, highlighting efficient use of equity to generate profits.
</li>
<li>
The company exhibits higher Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) of $1.76 Billion, which is 1.33x above the industry average, implying stronger profitability and robust cash flow generation.
</li>
<li>
The company has higher gross profit of $3.07 Billion, which indicates 1.08x above the industry average, indicating stronger profitability and higher earnings from its core operations.
</li>
<li>
The company's revenue growth of 12.32% is significantly below the industry average of 30.25%. This suggests a potential struggle in generating increased sales volume.
</li>
</ul>
<h3>Debt To Equity Ratio</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1728486024_0.png" alt="debt to equity" />
The debt-to-equity (D/E) ratio assesses the extent to which a company relies on borrowed funds compared to its equity.
Considering the debt-to-equity ratio in industry comparisons allows for a concise evaluation of a company's financial health and risk profile, aiding in informed decision-making.
By considering the Debt-to-Equity ratio, Regeneron Pharmaceuticals can be compared to its top 4 peers, leading to the following observations:
<ul>
<li>
Regeneron Pharmaceuticals demonstrates a stronger financial position compared to its top 4 peers in the sector.
</li>
<li>
With a lower debt-to-equity ratio of 0.1, the company relies less on debt financing and maintains a healthier balance between debt and equity, which can be viewed positively by investors.
</li>
</ul>
<h3>Key Takeaways</h3>
For Regeneron Pharmaceuticals, the PE, PB, and PS ratios are all low compared to peers in the Biotechnology industry, indicating potential undervaluation. On the other hand, the high ROE, EBITDA, and gross profit suggest strong profitability and operational efficiency relative to industry competitors. However, the low revenue growth rate may raise concerns about the company's ability to expand its market share in the future.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Inquiry Into Regeneron Pharmaceuticals's Competitor Dynamics In Biotechnology Industry

George Yancopoulos, co-founder and chief scientific officer of Regeneron Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>), has voiced concerns that the popular GLP-1s class of weight-loss drugs may lead to unintended health risks, particularly <a target="_blank" href="https://www.benzinga.com/general/biotech/24/05/38596483/regeneron-pharmaceuticals-targets-quality-weight-loss-in-latest-obesity-innovation" rel="noreferrer noopener">rapid muscle loss</a>.
Yancopoulos warned that unless this side effect is mitigated, these treatments could ultimately cause &#8220;more harm than good.&#8221; Clinical studies indicate that patients using GLP-1s, such as Novo Nordisk A/S&#8217; (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) Ozempic and Wegovy, experience muscle loss much faster than those who lose weight through diet and exercise.
U.S. pharmacy claims data analysis reveals that only one in four patients prescribed&nbsp;Wegovy&nbsp;and&nbsp;Ozempic continue their <a target="_blank" href="https://www.benzinga.com/general/biotech/24/07/39713169/only-25-patients-stick-with-novo-nordisks-wegovy-or-ozempic-after-2-years-a-study-shows-company-c" rel="noreferrer noopener">treatment after two years</a>.
In the Financial Times <a target="_blank" href="https://www.ft.com/content/094cbf1f-c5a8-4bb3-a43c-988bd8e2dea9" rel="noreferrer noopener">report</a>, Yancopoulos emphasized that patients often regain weight but with a higher fat-to-muscle ratio, which Yancopoulos described as &#8220;adding insult to injury.&#8221;
He expressed concerns that GLP-1s may trigger body composition changes that could lead to more harm than benefit in the long run when used in the real world.
A study published in the&nbsp;Journal of the American Medical Association&nbsp;(JAMA) revealed that patients, on average, achieved only a 3.7% weight reduction after one year on the drugs—lower than the results reported <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41168351/popular-weight-loss-drugs-like-ozempic-show-gap-between-clinical-trial-promises-and-real-world-us" rel="noreferrer noopener">in controlled trials</a>.
Regeneron is researching muscle-preserving treatments to pair with these weight-loss medications.
Regeneron is conducting a Phase 2 trial for trevogrumab, which blocks the hormone myostatin to promote muscle growth, in combination with Wegovy (semaglutide).
Topline results are expected in the second half of 2025.
In June, Regeneron <a target="_blank" href="https://diabetesjournals.org/diabetes/article/73/Supplement_1/34-OR/154774/34-OR-The-Effect-of-Combined-Activin-A-and" rel="noreferrer noopener">released</a> multiple ascending dose data from a Phase 1 study evaluating garetosmab (anti-activin A) and trevogrumab on body composition in healthy volunteers (n=34).
The data demonstrated that combination therapy led to greater-than-additive increases in lean mass while decreasing fat <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/06/39464192/regeneron-pharmaceuticals-approach-to-improve-quality-of-weight-loss-has-merit-gold" rel="noreferrer noopener">mass in healthy participants</a>.
In 2023, Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) acquired Versanis Bio&nbsp;for up to $1.925 billion in cash, bolstering its product profile of <a target="_blank" href="https://www.benzinga.com/markets/equities/23/07/33231176/why-eli-lilly-shares-are-surging-today" rel="noreferrer noopener">obesity-curbing drugs</a>.
Eli Lilly said bimagrumab can reduce fat mass while preserving muscle mass for people with obesity and obesity-related complications.
According to FT, Yancopoulos hinted that Regeneron is considering entering the GLP-1 space by developing its drug version despite the concern. However, he remains cautious, stating that GLP-1s may not be the ultimate solution to metabolic disease.
Price Action: REGN stock is down 0.23% tot $1,010.51 at the last check on Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/government/24/10/41207010/taiwan-semiconductor-strengthens-europes-semiconductor-base" target="_blank" rel="noreferrer noopener">Taiwan Semiconductor Strengthens Europe&#8217;s Semiconductor Base</a>.</li>
</ul>

Media

Regeneron Chief Flags Health Risks with Popular Weight-Loss Medications Like Ozempic, Says Company Targets Muscle Preservation For Its Obesity Drugs

Guidance

Regeneron Expects Acquired IPR&D Charge To Negatively Impact Each Of GAAP And Adj EPS For Q3 By Approximately $0.43

Regeneron Currently Expects Q3 Financial Results To Include An Acquired In-process Research And Development Charge Of Approximately $56M On Pre-tax Basis - Filing

Throughout the last three months, 24 analysts have evaluated Regeneron Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>), offering a diverse set of opinions from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">15</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $1194.29, a high estimate of $1300.00, and a low estimate of $1000.00. Surpassing the previous average price target of $1151.54, the current average has increased by 3.71%.
<img src="https://www.benzinga.com/files/images/story/2024/1728068423_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Regeneron Pharmaceuticals. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$1260.00</td>
<td>$1252.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$1252.00</td>
<td>$1282.00</td>
</tr>
<tr>
<td>Evan David Seigerman</td>
<td>BMO Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$1300.00</td>
<td>$1300.00</td>
</tr>
<tr>
<td>Srikripa Devarakonda</td>
<td>Truist Securities</td>
<td>Maintains</td>
<td>Buy</td>
<td>$1200.00</td>
<td>$1200.00</td>
</tr>
<tr>
<td>David Risinger</td>
<td>Leerink Partners</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$1077.00</td>
<td>$1175.00</td>
</tr>
<tr>
<td>Mohit Bansal</td>
<td>Wells Fargo</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$1200.00</td>
<td>$1200.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$1282.00</td>
<td>$1282.00</td>
</tr>
<tr>
<td>Olivia Brayer</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$1015.00</td>
<td>$1015.00</td>
</tr>
<tr>
<td>Olivia Brayer</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$1015.00</td>
<td>$1015.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$1282.00</td>
<td>$1250.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$1250.00</td>
<td>$1250.00</td>
</tr>
<tr>
<td>Christopher Raymond</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$1242.00</td>
<td>$1166.00</td>
</tr>
<tr>
<td>Chris Schott</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$1200.00</td>
<td>$1150.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$1240.00</td>
<td>$1232.00</td>
</tr>
<tr>
<td>Yatin Suneja</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Buy</td>
<td>$1300.00</td>
<td>$1180.00</td>
</tr>
<tr>
<td>Mohit Bansal</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$1200.00</td>
<td>$1125.00</td>
</tr>
<tr>
<td>Carter Gould</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$1220.00</td>
<td>$1200.00</td>
</tr>
<tr>
<td>Srikripa Devarakonda</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$1200.00</td>
<td>$1135.00</td>
</tr>
<tr>
<td>Tyler Van Buren</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$1200.00</td>
<td>$1030.00</td>
</tr>
<tr>
<td>Olivia Brayer</td>
<td>Cantor Fitzgerald</td>
<td>Raises</td>
<td>Neutral</td>
<td>$1000.00</td>
<td>$925.00</td>
</tr>
<tr>
<td>Christopher Raymond</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$1166.00</td>
<td>$1000.00</td>
</tr>
<tr>
<td>Yatin Suneja</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Buy</td>
<td>$1180.00</td>
<td>$1040.00</td>
</tr>
<tr>
<td>Matthew Harrison</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$1182.00</td>
<td>$1183.00</td>
</tr>
<tr>
<td>Carter Gould</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$1200.00</td>
<td>$1050.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Regeneron Pharmaceuticals. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Regeneron Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Regeneron Pharmaceuticals's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Regeneron Pharmaceuticals's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/REGN/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Regeneron Pharmaceuticals analyst ratings.</a>
<h2>Unveiling the Story Behind Regeneron Pharmaceuticals</h2>
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).
<h3>Regeneron Pharmaceuticals: A Financial Overview</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Revenue Growth: Regeneron Pharmaceuticals's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately 12.32%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Regeneron Pharmaceuticals's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 40.38% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Regeneron Pharmaceuticals's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 5.19% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Regeneron Pharmaceuticals's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 4.07%, the company showcases efficient use of assets and strong financial health.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.1.
<h2>Analyst Ratings: Simplified</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Closer Look at 24 Analyst Recommendations For Regeneron Pharmaceuticals

RBC Capital analyst Brian Abrahams maintains Regeneron Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) with a Outperform and raises the price target from $1252 to $1260.

RBC Capital Maintains Outperform on Regeneron Pharmaceuticals, Raises Price Target to $1260

Investors with a lot of money to spend have taken a bearish stance on Regeneron Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether this is an institution or just a wealthy individual, we don't know. But when something this big happens with REGN, it often means somebody knows something is about to happen.
Today, Benzinga's options scanner spotted 9 options trades for Regeneron Pharmaceuticals.
This isn't normal.
The overall sentiment of these big-money traders is split between 11% bullish and 88%, bearish.
Out of all of the options we uncovered, 8 are puts, for a total amount of $765,070, and there was 1 call, for a total amount of $40,000.
<h3>Projected Price Targets</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $650.0 to $1200.0 for Regeneron Pharmaceuticals during the past quarter. 
<h3>Insights into Volume &amp; Open Interest</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Regeneron Pharmaceuticals's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Regeneron Pharmaceuticals's significant trades, within a strike price range of $650.0 to $1200.0, over the past month.
<h3>Regeneron Pharmaceuticals Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727980469_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th style="text-align: right;">Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>REGN</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$7.7</td>
<td>$0.05</td>
<td>$6.0</td>
<td>$650.00</td>
<td>$300.0K</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">500</td>
</tr>
<tr>
<td>REGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$22.5</td>
<td>$16.6</td>
<td>$22.5</td>
<td>$830.00</td>
<td>$234.0K</td>
<td style="text-align: right;">23</td>
<td style="text-align: right;">120</td>
</tr>
<tr>
<td>REGN</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$50.6</td>
<td>$45.7</td>
<td>$49.0</td>
<td>$960.00</td>
<td>$49.0K</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">10</td>
</tr>
<tr>
<td>REGN</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$52.1</td>
<td>$44.1</td>
<td>$49.0</td>
<td>$960.00</td>
<td>$49.0K</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">10</td>
</tr>
<tr>
<td>REGN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/19/25</td>
<td>$80.0</td>
<td>$71.0</td>
<td>$80.0</td>
<td>$1200.00</td>
<td>$40.0K</td>
<td style="text-align: right;">102</td>
<td style="text-align: right;">5</td>
</tr>
</tbody>
</table>

<h3>About Regeneron Pharmaceuticals</h3>
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).
After a thorough review of the options trading surrounding Regeneron Pharmaceuticals, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Present Market Standing of Regeneron Pharmaceuticals</h3>
<ul>
<li>Currently trading with a volume of 421,493, the REGN's price is down by 0.0%, now at $1040.27. </li>
<li>RSI readings suggest the stock is currently may be oversold.</li>
<li>Anticipated earnings release is in 28 days.</li>
</ul>
<h3>Professional Analyst Ratings for Regeneron Pharmaceuticals</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $1215.8.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from RBC Capital keeps a Outperform rating on Regeneron Pharmaceuticals with a target price of $1252. 
&#x2A; In a cautious move, an analyst from Leerink Partners downgraded its rating to Market Perform, setting a price target of $1077. 
&#x2A; Reflecting concerns, an analyst from RBC Capital lowers its rating to Outperform with a new price target of $1250. 
&#x2A; An analyst from Truist Securities downgraded its action to Buy with a price target of $1200. 
&#x2A; An analyst from BMO Capital has revised its rating downward to Outperform, adjusting the price target to $1300. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Regeneron Pharmaceuticals, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Market Whales and Their Recent Bets on REGN Options

Regeneron Pharmaceuticals's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NYSE">REGN</a>) short percent of float has fallen 5.97% since its last report. The company recently reported that it has 1.98 million shares sold short, which is 1.89% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.18 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Regeneron Pharmaceuticals Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727977519_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Regeneron Pharmaceuticals has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Regeneron Pharmaceuticals's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Regeneron Pharmaceuticals's peer group average for short interest as a percentage of float is 5.95%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

(REGN) - Analyzing Regeneron Pharmaceuticals's Short Interest

Sanofi&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sny#NASDAQ">SNY</a>) and partner Regeneron&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/regn#NASDAQ">REGN</a>) announced that the FDA has approved their blockbuster drug, Dupixent, for its sixth indication &mdash; chronic obstructive pulmonary disease (COPD) &mdash; in the United States. The approved indication is as an add-on maintenance treatment of adults with inadequately controlled COPD and an eosinophilic phenotype. With this approval, Dupixent became the first biologic treatment approved for COPD in the United States.
Dupixent was approved for treating COPD with raised blood eosinophils in the EU in July 2024. Dupixent was also approved for the COPD indication in China last week.
Sanofi&#39;s stock has gained 16.0% so far this year compared with an increase of 20.2% for the large cap <a href="https://www.zacks.com/stocks/industry-rank/industry/large-cap-pharmaceuticals-225">pharmaceutical industry</a>.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/e4/79621.jpg?v=1565371588" style="height:310px; width:624px" />
Image Source: Zacks Investment Research
The approval for COPD, a respiratory disease that causes progressive lung function decline, was based on data from two studies. The NOTUS and BOREAS studies met their primary endpoint by showing that Dupixent significantly reduced moderate or severe acute COPD exacerbations by 30% and 34%, respectively. Dupixent also showed improvements in lung function and health-related quality of life compared to placebo.
Earlier this year, the FDA extended its decision on a supplemental biologics license application seeking approval of Dupixent for COPD from June 27 to Sept. 27.
<h3>Dupixent &ndash; Key Top-Line Driver For SNY, REGN</h3>
Dupixent is currently approved in several countries, including the United States and EU, for five other type II inflammatory diseases, namely severe chronic rhinosinusitis with nasal polyposis, severe asthma, moderate-to-severe atopic dermatitis, eosinophilic esophagitis and prurigo nodularis.
Dupixent is being jointly marketed by Regeneron and&nbsp;Sanofi&nbsp;under a global collaboration agreement. Sanofi records global net product sales of Dupixent, while Regeneron records its share of profits/losses in connection with the global sales of the drug. The approval for the COPD indication can significantly boost sales of Dupixent. Some analysts expect total sales of Dupixent for COPD to be around $6 billion.
Dupixent is a key top-line driver for both Sanofi and Regeneron on strong demand trends. In the first half of 2024, Dupixent generated global product sales of $&euro;6.1 billion, which were recorded by Sanofi, representing growth of 27.1% at a constant exchange rate. Sanofi expects Dupixent to achieve more than &euro;13 billion in sales in 2024.
For Regeneron, Dupixent generated collaboration revenues of $2.06 billion in the first half, up 18% year over year.
<h2>SNY Zacks Rank and Other Stocks to Consider</h2>
Sanofi currently has a Zacks Rank #2 (Buy).
<div class="chart_embed">
<h3>Sanofi Stock Price and Consensus</h3>
<a href="https://www.zacks.com/stock/chart/SNY/price-consensus-chart?icid=chart-SNY-price-consensus-chart"><img alt="Sanofi Price and Consensus" src="https://staticx-tuner.zacks.com/images/charts/44/1727692069.png" style="height:287px; width:624px" title="" /> </a>
<a href="https://www.zacks.com/stock/chart/SNY/price-consensus-chart?icid=chart-SNY-price-consensus-chart">Sanofi price-consensus-chart</a> | <a href="https://www.zacks.com/stock/quote/SNY?icid=chart-SNY-price-consensus-chart">Sanofi Quote</a>
</div>
Some other top-ranked drug/biotech companies are Eli Lilly (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/lly#NYSE">LLY</a>) and Pfizer (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/pfe#NYSE">PFE</a>). While Lilly sports a Zacks Rank #1 (Strong Buy), Pfizer has a Zacks Rank #2. You can see <a href="https://www.zacks.com/stocks/buy-list/?ADID=zp_1link&amp;ICID=zpi%20_1link">the complete list of today&#39;s Zacks #1 Rank stocks here</a>.
Estimates for Lilly&#39;s 2024 earnings have risen from $13.79 to $16.49 per share over the past 60 days. For 2025, earnings estimates have risen from $19.44 to $23.97 per share over the same timeframe. Year to date, Lilly&#39;s stock has risen 50.5%.
Lilly beat estimates in each of the last four quarters, delivering a four-quarter average earnings surprise of 69.07%.
The Zacks Consensus Estimate for Pfizer&#39;s earnings has risen from $2.38 to $2.62 per share for 2024 over the past 60 days, while that for 2025 has risen from $2.74 per share to $2.85 per share. Pfizer&#39;s shares have risen 1.0% year to date.
Pfizer beat estimates in each of the last four quarters, delivering a four-quarter average earnings surprise of 69.82%.
<a href="https://www.zacks.com/">Zacks Investment Research</a>

Sanofi, Regeneron's Dupixent Gets FDA Approval For COPD

Regeneron Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) has outperformed the market over the past 5 years by 15.76% on an annualized basis producing an average annual return of 29.94%. Currently, Regeneron Pharmaceuticals has a market capitalization of $115.55 billion. 
Buying $100 In REGN: If an investor had bought $100 of REGN stock 5 years ago, it would be worth $373.39 today based on a price of $1048.18 for REGN at the time of writing.
<h3>Regeneron Pharmaceuticals's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727708425_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In This Stock 5 Years Ago Would Be Worth $400 Today

These ten large-cap stocks were the worst performers in the last week. Are they in your portfolio?
<ol>
<li>Summit Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>) shares fell 14.37% last week after Citigroup downgraded the stock from <a href="https://www.benzinga.com/quote/smmt/analyst-ratings" target="_blank" rel="noreferrer noopener">Buy to Neutral</a> but raised its price target from $19 to $23.</li>
<li>MakeMyTrip Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMYT#NASDAQ">MMYT</a>) stock plummeted 12.46%.</li>
<li>Medpace Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MEDP#NASDAQ">MEDP</a>) stock fell 9.37% after Jefferies downgraded the stock from Buy to Hold and <a href="https://www.benzinga.com/quote/medp/analyst-ratings" target="_blank" rel="noreferrer noopener">cut its price target from $415 to $345</a>.</li>
<li>Regeneron Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) stock lost 8.94% last week after Leerink Partners <a href="https://www.benzinga.com/quote/regn/analyst-ratings" target="_blank" rel="noreferrer noopener">downgraded it</a> from Outperform to Market Perform and lowered its price target from $1,175 to $1,077.</li>
<li>Global Payments Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPN#NYSE">GPN</a>) shares dived 8.74% after the company guided <a href="https://www.benzinga.com/pressreleases/24/09/b41024786/global-payments-shares-updated-strategy-and-medium-term-outlook-at-investor-conference" target="_blank" rel="noreferrer noopener">FY25 EPS growth below estimates</a>, and multiple firms downgraded the stock and<a href="https://www.benzinga.com/quote/gpn/analyst-ratings" target="_blank" rel="noreferrer noopener"> cut their respective price targets</a>.</li>
<li>Affirm Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFRM#NASDAQ">AFRM</a>) stock lost 8.39% last week. There was no company-specific news to justify the price loss.</li>
<li>Super Micro Computer, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) shares dipped 8.21% following a report indicating the company is being probed by the Department of Justice following an August short <a href="https://www.benzinga.com//node/41052423" target="_blank" rel="noreferrer noopener">report from</a><a href="https://www.benzinga.com//node/41052423" target="_blank" rel="noreferrer noopener"> Hindenburg Research</a>.</li>
<li>TechnipFMC plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FTI#NYSE">FTI</a>) stock fell 6.10% amid reports suggesting Saudi Arabia may raise crude oil output.</li>
<li>First Citizens BancShares, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FCNCA#NASDAQ">FCNCA</a>) stock lost 6.09% last week after Wedbush analyst <a href="https://www.benzinga.com/quote/fcnca/analyst-ratings" target="_blank" rel="noreferrer noopener">downgraded the stock</a> from Outperform to Neutral and lowered the price target from $2,450 to $2,150.</li>
<li>ServiceNow, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOW#NYSE">NOW</a>) stock fell 5.93% from pressure following the DOJ&#8217;s Carahsoft investigation.</li>
</ol>
Also Read:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/24/09/41082440/chinese-stocks-dominate-jd-com-and-temu-parent-pdd-are-among-top-10-large-cap-gainers-last-week-se" target="_blank" rel="noreferrer noopener">Chinese Stocks Dominate &#8211; JD.com And Temu Parent PDD Are Among Top 10 Large Cap Gainers Last Week (Sept 23-Sept 27): Are The Others In Your Portfolio?</a></li>
</ul>
Photo via Company

Movers

AFRM

FCNCA

KNTK

MEDP

MMYT

SMCI

SMMT

Regeneron Pharma, Super Micro Computer And Global Payments Are Among Top 10 Large Cap Losers Last Week (Sept 23-Sept 27): Are The Others In Your Portfolio?

On Friday, the FDA approved Regeneron Pharmaceuticals, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) and Sanofi SA&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) Dupixent&nbsp;(dupilumab) as an add-on maintenance treatment of inadequately controlled chronic obstructive pulmonary disease (COPD) and an <a target="_blank" href="https://www.benzinga.com/pressreleases/24/09/g41067118/dupixent-dupilumab-approved-in-the-u-s-as-the-first-ever-biologic-medicine-for-patients-with-copd" rel="noreferrer noopener">eosinophilic phenotype</a>, generally known as &#8220;smoker&#8217;s lung.&#8221;
Dupixent is the first biologic medicine approved in the U.S. to treat these patients.&nbsp;&nbsp;
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40814475/sanofi-regeneron-drug-dupixent-shows-successful-treatment-of-patients-with-inflammatory-skin-dise" rel="noreferrer noopener">Sanofi, Regeneron Drug Dupixent Shows Successful Treatment Of Patients With Inflammatory Skin Disease</a>.
The FDA approval is based on data from two Phase 3 trials (<a target="_blank" href="https://www.globenewswire.com/Tracker?data=7kKUkEN_j7dfFFaJgSlNFzKZoO4mFwp3ozmSi0rwdtS0dUmDMMLRg3ML03GEfgLzJP_Yg33hoRBP-3IabEFUjTEGB_rbTRFqm_JL_llzjsfHVLX2ednnpkFojo7lpUCTxdCo_2YiyMr0ctlswWAwXOheTav4f6f3NjyHRNKi9AkNKqyHtmSD_t9WycxSdyDJF-7MluPxoOJfAy9kkVjGMA==" rel="noreferrer noopener">BOREAS</a> and&nbsp;<a target="_blank" href="https://www.globenewswire.com/Tracker?data=6PGgHroz2kXLk3EuPbMe_MIJ-5vFWDjqk9axy8qZd2P7xQ3L3g2ASjHZ8xt1uzCTdZuMSDrpF3jIDhOGYYWxNY22Nyhv04bkd8VwfNHxSVov8kQjYXAerk1eaKGoDXJDxNmLd9JxB76ojM5ft65Yy_p10fVEAMfMBBDCl7C-sv2-eIX7C8dxYBsnfHK7AYcbsomWIUjlfALjFhRk2bqT3w==" rel="noreferrer noopener">NOTUS</a>) that evaluated the efficacy and safety of Dupixent compared to placebo in adults currently on maximal standard-of-care inhaled therapy (nearly all on triple therapy).
<ul>
<li>Patients who received Dupixent in BOREAS (n=468) and NOTUS (n=470) experienced the following outcomes, respectively, compared to placebo (BOREAS n=471; NOTUS n=465):</li>
<li>The primary endpoint is a 30% and 34% reduction in the annualized rate of moderate or severe COPD exacerbations over 52 weeks.</li>
<li>74mL and 68mL numerically greater improvements in post-bronchodilator FEV1 from baseline at week 12 compared to placebo, sustained at 52 weeks. Statistically significant improvements of similar magnitude were observed in pre-bronchodilator FEV1 from baseline at 12 and 52 weeks, a key secondary endpoint.</li>
<li>51% response in a health-related quality of life measure in both trials compared to 43% and 47% with placebo at 52 weeks.</li>
</ul>
About half of COPD patients continue to experience exacerbations despite being on triple inhaled therapy.
In the U.S., approximately 300,000 people live with inadequately controlled COPD and an eosinophilic phenotype.
Patients with an eosinophilic phenotype contribute to a ~30% increase in exacerbations and an increased risk of COPD-related re-hospitalizations within a year.
Today, China&#8217;s National Medical Products Administration also approved Dupixent&nbsp;(dupilumab) as an add-on maintenance treatment for adults with uncontrolled chronic obstructive pulmonary disease characterized by <a target="_blank" href="https://www.benzinga.com/pressreleases/24/09/g41063987/dupixent-dupilumab-approved-in-china-as-the-first-ever-biologic-medicine-for-patients-with-chronic" rel="noreferrer noopener">raised blood eosinophils</a>.
The approval is based on BOREAS and NOTUS Phase 3 trial results.
Price Action:&nbsp;At last check Friday, REGN stock was up 2.86% at $1,069.75, and SNY stock was up 1.49% at $57.85.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/24/09/41067826/federal-investigations-continue-for-psychiatric-hospital-chain-operator-acadia-healthcare-even-aft" target="_blank" rel="noreferrer noopener">Federal Investigations Continue For Psychiatric Hospital Chain Operator Acadia Healthcare Even After $20M Settlement Over False Claims Allegations</a>.</li>
</ul>

FDA Approves Regeneron/Sanofi's Blockbuster Dupixent For Smoker's Lung Disease

Dupixent is indicated&nbsp;for the approximately 300,000 adults in the U.S. with inadequately controlled&nbsp;chronic obstructive pulmonary disease (COPD)&nbsp;and&nbsp;an eosinophilic phenotype &nbsp;
Following recent&nbsp;approvals in the EU and China, the U.S. approval is based on two landmark Phase 3 trials that showed Dupixent achieved significant reduction in exacerbations, and also showed improvements in lung function and health-related quality of life compared to placebo
Dupixent is the leading biologic medicine for all of its FDA-approved indications in new-to-brand prescriptions, and the most prescribed biologic by pulmonologists in the U.S.
TARRYTOWN, N.Y. and PARIS, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved Dupixent&#xAE; (dupilumab) as an add-on maintenance treatment of adults with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype. Dupixent is the first biologic medicine approved in the U.S. to treat these patients.&nbsp;&nbsp;

Global

Regeneron Pharmaceuticals Announces Dupixent Approved In The U.S. As The First-Ever Biologic Medicine For Patients With COPD

Approval follows EU approval of Dupixent for adults with COPD with raised blood eosinophils, and is based on two landmark Phase 3 trials showing Dupixent significantly reduced exacerbations, improved lung function and also improved health-related quality of life. 
&nbsp;
COPD is the most prevalent chronic respiratory disease in China, and is a priority within the government&#39;s Healthy China 2030 public health plan.
Dupixent is now approved in four indications across respiratory and dermatological diseases in China.

Regeneron Pharmaceuticals And Sanofi Today Announced That  National Medical Products Administration In China Has Approved Dupixent (Dupilumab) As An Add-on Maintenance Treatment For Adults With Uncontrolled Chronic Obstructive Pulmonary Disease

On CNBC's &#8220;<a href="https://www.cnbc.com/video/2024/09/25/final-trades-trane-tech-american-tower-regeneron-and-taiwan-semi.html">Halftime Report Final Trades</a>,&#8221; Stephen Weiss of Short Hills Capital Partners said he still finds Taiwan Semiconductor Manufacturing Company Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) <a href="https://www.benzinga.com/government/24/09/41007184/taiwan-semi-secures-7-5b-boost-for-arizona-expansion-aims-for-advanced-chip-production-report">cheap</a>.
On Monday, Taiwan Semiconductor Manufacturing bagged the government's approval for an additional $7.5 billion infusion into Taiwan Semiconductor Arizona unit, the Taipei Times cited the Department of Investment Review statement.
Amy Raskin of Chevy Chase Trust named Regeneron Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>).
Chief District Judge Thomas Kleeh denied Regeneron Pharmaceuticals' effort to prevent the sale of Amgen Inc's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) Eylea biosimilar. Regeneron filed a notice of its appeal to the U.S. Court of Appeals <a href="https://www.benzinga.com/general/biotech/24/09/41012464/why-is-regeneron-pharmaceuticals-stock-trading-lower-on-tuesday">for the Federal Circuit</a>.
 Don't forget to check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
Kari Firestone of Aureus Asset Management picked American Tower Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMT#NYSE">AMT</a>) as her final trade.
On Sept. 23, JP Morgan analyst Philip Cusick maintained American Tower with an Overweight rating and raised the price target from $240 to $250.
Joseph M. Terranova of Virtus Investment Partners named Trane Technologies plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TT#NYSE">TT</a>).
On July 31, Trane Technologies reported better-than-expected second-quarter financial results and raised its FY24 guidance. Revenues grew 13% Y/Y to $5.31 billion, surpassing the consensus of $5.13 billion. Bookings increased 19% Y/Y to$5.34 billion in the quarter. Adjusted EPS of $3.30 surpassed the street view of $3.08.
Price Action:
<ul>
<li>Taiwan Semiconductor gained 0.2% to close at $182.35 during Wednesday's session.</li>
<li>Regeneron Pharmaceuticals shares fell 1.4% to settle at $1,031.15 on Wednesday.</li>
<li>American Tower fell 0.4% to close at $235.63 during Wednesday's session.</li>
<li>Trane Technologies shares gained 1% to close at $387.70 on Wednesday.</li>
</ul>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/news/24/09/41024505/top-5-industrials-stocks-that-may-collapse-in-q3">Top 5 Industrials Stocks That May Collapse In Q3</a></li>
</ul>
Image: Shutterstock

Long Ideas

Taiwan Semiconductor, American Tower, Trane Technologies And A Health Care Stock On CNBC's 'Final Trades'

CNBC Halftime Report Final Trades: Trane Technologies, American Tower, Regeneron Pharmaceuticals, Taiwan Semiconductor Manufacturing

The biotech industry is poised for significant growth, fueled by advanced technologies, the increased commercialization of new therapeutics, and increased R&D spending on treatments for new and rare diseases. Hence, investors should consider strong biotech stocks such as Amgen (AMGN), Regeneron Pharmaceuticals (REGN), and Biogen (BIIB), which could deliver big gains. Keep reading… The biotech sector is rapidly expanding due to the rising global demand for therapeutics, and the development, manufacturing, and commercialization of medicines for various diseases, such as cancer and neurodegenerative disorders. This dynamic landscape presents savvy investors with opportunities to capitalize on significant profit potential.
In this favorable environment, investors might consider investing in fundamentally strong biotech stocks like Amgen Inc. (<a href="https://stocknews.com/stock/AMGN/">AMGN</a>), Regeneron Pharmaceuticals, Inc. (<a href="https://stocknews.com/stock/REGN/">REGN</a>), and Biogen Inc. (<a href="https://stocknews.com/stock/BIIB/">BIIB</a>) for potential substantial gains.
The biotech sector targets new and rare diseases, emphasizing innovative vaccines and therapies. The increasing incidence of various illnesses demands greater R&amp;D investments and advancements in biotechnology to enhance prevention and treatment across all age groups. This growing demand for personalized medicine, coupled with supportive government initiatives, significantly boosts sales in the biotech industry.
Consequently, the global biotechnology market is projected to reach $3.88 trillion by 2030, growing at a <a href="https://www.grandviewresearch.com/industry-analysis/biotechnology-market">CAGR of 14%</a>. Notably, the future of biotech appears promising, driven by sophisticated innovations such as gene editing, CRISPR diagnostics, bioprinting, and tissue engineering. Moreover, the integration of AI enhances accessibility and affordability, instilling optimism in the biotech sector's potential.
Furthermore, investors' interest in biotech stocks is evident from the SPDR S&amp;P Biotech ETF's (<a href="https://stocknews.com/stock/XBI/">XBI</a>) 36% returns over the past year. Considering these conducive trends, let's analyze the fundamental aspects of the three <a href="https://stocknews.com/category/biotech/">Biotech</a> picks, beginning with the third choice.
Stock #3: Amgen Inc. (<a href="https://stocknews.com/stock/AMGN/">AMGN</a>)
AMGN discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/haematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. Its product portfolio includes Enbrel, Neulasta, Prolia, and Xgeva.
On June 6, 2024, AMGN announced FDA approval of BLINCYTO for CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (B-ALL) in the consolidation phase. This marks the third indication for BLINCYTO and demonstrated superior overall survival versus chemotherapy alone.
On August 20, 2024, AMGN announced that Otezla (apremilast) is now available in the U.S. for treating moderate to severe plaque psoriasis in children and adolescents aged 6-17. It is the first FDA-approved oral treatment for this condition in this age group.
AMGN's trailing-12-month <a href="https://www.investopedia.com/terms/g/gross_profit_margin.asp">gross profit margin</a> of 63.41% is 10.6% higher than the industry average of 57.35%. Likewise, its trailing-12-month EBIT margin and levered FCF margin of 20.99% and 9.74% are 628% and 492.5% higher than the industry averages of 2.88% and 1.64%, respectively.
During the fiscal second quarter, which ended on June 30, 2024, AMGN's total revenues and non-GAAP operating income increased by 20.1% and 10.2% year-over-year, reaching $8.39 billion and $3.87 billion, respectively. Moreover, its non-GAAP net income grew marginally compared to the previous year, reaching $2.69 billion. Also, its non-GAAP earnings per share was $4.97.
Analysts expect AMGN's revenue for the quarter ending September 30, 2024, to increase 23.3% year-over-year to $8.51 billion. Its EPS for the same quarter is expected to grow 3.7% year-over-year to $5.14. The company surpassed the Street EPS estimates in three of the trailing four quarters. Over the past year, the stock has gained 25.4%, closing the last trading session at $335.61.
AMGN's <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a> reflect its positive prospects. It has an overall B rating, equating to Buy in our proprietary rating system. The POWR Ratings are calculated by considering 118 distinct factors, with each factor weighted to an optimal degree.
AMGN has a B grade for Quality. Within the <a href="https://stocknews.com/category/biotech/">Biotech</a> industry, it is ranked #17 out of 335 stocks. <a href="https://stocknews.com/stock/AMGN/">Click here</a> for the additional POWR Ratings of AMGN (Growth, Value, Momentum, Stability, and Sentiment).
Stock #2: Regeneron Pharmaceuticals, Inc. (<a href="https://stocknews.com/stock/REGN/">REGN</a>)
REGN discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection, Dupixent injection, Libtayo injection, Praluent injection, REGEN-COV for COVID-19, and Kevzara solution.
On September 13, 2024, REGN and Sanofi announced that the FDA approved Dupixent for adolescents aged 12-17 with chronic rhinosinusitis with nasal polyps (CRSwNP). Dupixent is now the first and only treatment available for this age group with inadequately controlled CRSwNP.
On August 26, 2024, REGN announced that the European Commission approved Ordspono (odronextamab) for treating relapsed/refractory follicular lymphoma and diffuse large B-cell lymphoma. This is REGN's first bispecific antibody approval, offering an off-the-shelf treatment option with the potential for complete remission.
In terms of the trailing-12-month levered FCF margin, REGN's 15.50% is significantly higher than the 1.64% industry average. Similarly, its 30.14% trailing-12-month EBIT margin is 945.6% higher than the 2.88% industry average. Moreover, its 5.50% trailing-12-month Capex / Sales is 65.5% higher than the industry average of 3.32%.
In the fiscal second quarter, which ended on June 30, 2024, REGN's revenues amounted to $3.55 billion indicating a 12.3% increase year-over-year. Likewise, the company's non-GAAP net income rose 14.3% from the year-ago value to $1.35 billion, while its non-GAAP net income per share grew 12.9% year-over-year to $11.56.
Street expects REGN's EPS and revenue for the quarter ending September 30, 2024, to increase 1.5% and 8.7% year-over-year to $11.76 and $3.66 billion, respectively. It surpassed the consensus EPS estimates in three of the trailing four quarters. Over the past year, the stock has gained 32.4%, closing the last trading session at $1,091.98.
REGN's positive outlook is reflected in its POWR Ratings. It has an overall rating of B, equating to a Buy in our proprietary rating system.
It has a B grade for Value and Quality. Within the same industry, it is ranked #9. Beyond what we stated above, we also have given REGN grades for Growth, Momentum, Stability, and Sentiment. Get all the REGN ratings <a href="https://stocknews.com/stock/REGN/">here</a>.
Stock #1: Biogen Inc. (<a href="https://stocknews.com/stock/BIIB/">BIIB</a>)
BIIB discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Asia, and internationally.
On August 22, 2024, BIIB and Eisai announced that their Alzheimer's drug Leqembi (lecanemab) was authorized for early Alzheimer's treatment in Great Britain. It is the first medicine in Europe targeting the underlying cause of Alzheimer's disease to be approved.
In terms of the trailing-12-month EBITDA margin, BIIB's 28.22% is 331.2% higher than the 6.54% industry average. Likewise, its 76.45% trailing-12-month gross profit margin is 33.3% higher than the 57.35% industry average. In addition, its 13.09% trailing-12-month levered FCF margin is 696.4% higher than the 1.64% industry average.
For the fiscal second quarter (ended June 30, 2024), BIIB's total revenue increased marginally year-over-year to $2.46 billion. Its non-GAAP net income attributable for the quarter amounted to $770.90 million, or $5.28 per share, up 31.9% and 31.3%, respectively, from the same period last year. Additionally, its free cash flow rose 42.4% year-over-year to $592.30 million.
For the quarter ending December 31, 2024, BIIB's EPS and revenue are expected to increase 14.7% and 2.4% year-over-year to $3.38 and $2.44 billion, respectively. BIIB surpassed the EPS estimates in three of the trailing four quarters. Over the past month, the stock has declined 4.5% to close the last trading session at $195.81.
It's no surprise that BIIB has an overall rating of A, which translates to a Strong Buy in our proprietary rating system.
It is ranked #7 in the Biotech industry. It has an A grade for Value and a B for Growth. <a href="https://stocknews.com/stock/BIIB/">Click here</a> to see BIIB's Momentum, Stability, Sentiment, and Quality ratings.
What To Do Next?
Get your hands on this special report with 3 low priced companies with tremendous upside potential even in today's volatile markets:
<a href="https://report.stocknews.com/free-report/3stocks/?formplacement=artbotad_3s">3 Stocks to DOUBLE This Year &gt;</a>

<hr />
AMGN shares were trading at $332.28 per share on Tuesday afternoon, down $3.33 (-0.99%). Year-to-date, AMGN has gained 17.91%, versus a 20.81% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Abhishek Bhuyan</h2> <img src='https:/wp-content/uploads/2023/07/ABhuyan.jpg' style="float:left; padding:5px;width:125px;">Abhishek embarked on his professional journey as a financial journalist due to his keen interest in discerning the fundamental factors that influence the future performance of financial instruments.<a href="https://stocknews.com/authors/?author=abhishek-bhuyan">More...</a>The post <a href=https://stocknews.com/news/amgn-regn-biib-3-biotech-stocks-that-could-deliver-big-gains/>3 Biotech Stocks That Could Deliver Big Gains</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Biotech Stocks That Could Deliver Big Gains

Genomics is on the brink of revolutionizing healthcare with breakthroughs that could redefine treatment and diagnosis. As this field rapidly evolves, investing in fundamentally sound genomics stocks like Regeneron Pharmaceuticals (REGN), Alnylam Pharmaceuticals (ALNY), and Illumina (ILMN) could be beneficial. Read more… Over the past two decades, the cost of gene sequencing has plummeted, turning genomics into a cutting-edge field with enormous potential. Thanks to substantial investments and waves of research funding, the industry is making significant strides in understanding and treating a range of genetic disorders and complex diseases.
In this rapidly evolving landscape, fundamentally sound companies like Regeneron Pharmaceuticals, Inc. (<a href="https://stocknews.com/stock/REGN/">REGN</a>), Alnylam Pharmaceuticals, Inc. (<a href="https://stocknews.com/stock/ALNY/">ALNY</a>), and Illumina, Inc. (<a href="https://stocknews.com/stock/ILMN/">ILMN</a>) are at the forefront of transforming healthcare.
Genomics is not just about unlocking the secrets of DNA; it's about applying that knowledge to real-world medical treatments. By understanding the unique genetic code of individuals, doctors can now offer more precise diagnostics and personalized treatments for conditions that range from common cancers to rare genetic disorders. It's an approach that brings us closer to an era of truly personalized medicine, where your DNA guides your healthcare plan.
Sales of next-generation genomic medicines are expected to <a href="https://ascent.usbank.com/private-capital-management/ascent-resources-and-insights/investment-strategies/investing-in-genomics.html">hit $84 billion by 2028</a>, driven by successful clinical trials and the growing need for new treatments. Moreover, the global genomics market is projected to grow from $39.53 billion in 2024 to $157.47 billion by 2033 at a <a href="https://www.biospace.com/genomics-market-size-to-hit-usd-157-47-billion-by-2033#:~:text=The%20global%20genomics%20market%20size,period%20(2024%2D2033).">CAGR of 16.6%</a>.
Given these encouraging trends, let's look at the fundamentals of the top <a href="https://stocknews.com/category/biotech/">Biotech</a> stocks, beginning with the third choice.
Stock #3: Alnylam Pharmaceuticals, Inc. (<a href="https://stocknews.com/stock/ALNY/">ALNY</a>)
ALNY focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases.
On April 30, 2024, ALNY and Medison Pharma, a global pharma company focused on providing access to highly innovative therapies for patients in international markets, announced a further expansion of their existing partnership in Central &amp; Eastern Europe and Israel also to include selected markets in LATAM and APAC and additional international markets.
This partnership is expected to ensure that ALNY's commercial therapies are available across multiple international markets, thus enhancing their income streams.
ALNY's trailing-12-month gross profit and EBIT margins of 87% and 4.38% are 50.5% and 64.7% higher than their respective industry averages of 57.81% and 2.66%. Also, its trailing-12-month levered FCF margin of 18.10% compares to the industry average of 1.60%.
During the fiscal second quarter that ended June 30, 2024, ALNY's net product revenues increased 34.1% year-over-year to $410.09 million. Its non-GAAP operating income came in at $137.90 million versus a year-ago operating loss of $154.03 million. Also, the company's non-GAAP <a href="https://www.investopedia.com/terms/n/netincome.asp">net income</a> amounted to $73.77 million or $0.56 per share, compared to a loss of $201.62 million or $1.62 per share recorded last year.
Analysts predict ALNY's revenue for the current year (ending December 2024) to increase 20.5% year-over-year to $2.20 billion. Further, its revenues are expected to register a 13.2% growth from the prior year, settling at $2.49 billion. It is no surprise that the company has topped the consensus revenue estimates in three of the trailing four quarters.
Over the past six months, ALNY's stock has surged 85.3% to close the last trading session at $273.15.
ALNY's bright prospects are reflected in its <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a>. The stock has an overall rating of B, equating to a Buy in our proprietary rating system. The POWR Ratings assess stocks by 118 different factors, each with its own weighting.
It has an A grade for Sentiment and a B for Quality. ALNY is ranked #28 among 335 stocks in the <a href="https://stocknews.com/category/biotech/">Biotech</a> industry. <a href="https://stocknews.com/stock/ALNY/">Click here</a> to access additional ALNY ratings (Growth, Value, Momentum, and Stability).
Stock #2: Illumina, Inc. (<a href="https://stocknews.com/stock/ILMN/">ILMN</a>)
ILMN develops, manufactures, and markets life science tools and integrated systems for large-scale genetic variation and function analysis. It operates through the Core Illumina and GRAIL segments. It provides sequencing and array-based instruments and consumables, whole-genome sequencing, genotyping, NIPT, and product support services.
On July 9, the company acquired Fluent BioSciences, a company known for its advanced single-cell technology. This acquisition strengthens ILMN's multiomics growth strategy by offering its customers advanced capabilities in single-cell research and enabling them to provide more comprehensive solutions to their customers.
ILMN's trailing-12-month EBIT margin of 4.63% is 80% higher than the industry average of 2.57%. Likewise, its 14.34% trailing-12-month EBITDA margin is 132.7% above the industry average of 6.16%. Also, its trailing-12-month levered FCF margin of 19.39% compares to the industry average of 1.61%.
In the second quarter that ended June 30, 2024, ILMN reported a total revenue of $1.11 billion with a gross margin of 64.8%. Its non-GAAP operating profit rose 2.4% from the year-ago value to $84 million. The company's non-GAAP net income and EPS came in at $57 million and $0.36, up 14% and 12.5% year-over-year, respectively.
Street expects ILMN's EPS for the fiscal third quarter (ending September 2024) to increase 164.7% year-over-year to $0.87, while its revenue is forecasted to be $1.08 billion. Moreover, it surpassed the consensus revenue estimates in three of the trailing four quarters, which is impressive.
The stock has gained 21.2% over the past three months to close the last trading session at $130.97.
ILMN's POWR Ratings reflect this promising outlook. The stock has an overall rating of B, equating to a Buy in our proprietary rating system.
It also has a B grade for Growth, Sentiment, and Quality. Within the same industry, it is ranked #24. To see the other ILMN ratings for Value, Momentum, and Stability, <a href="https://stocknews.com/stock/ILMN/">click here</a>.
Stock #1: Regeneron Pharmaceuticals, Inc. (<a href="https://stocknews.com/stock/REGN/">REGN</a>)
REGN discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases. Its product portfolio includes EYLEA, Dupixent, Libtayo, Praluent, REGEN-COV, Kevzara solution, and ARCALYST, among other injections.
On September 13, the U.S. Food and Drug Administration (FDA) approved the use of Dupixent&#xAE; (dupilumab) as an add-on maintenance treatment for adolescent patients aged 12 to 17 years with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP). This approval expands the initial June 2019 FDA approval in CRSwNP for patients aged 18 years and older.
The stock's trailing-12-month EBITDA and levered FCF margins of 33.50% and 15.50% are considerably higher than the industry averages of 6.16% and 1.61%, respectively. Similarly, its trailing-12-month EBIT margin of 30.14% compares to the industry average of 2.57%.
REGN's net revenues for the second quarter (ended June 2024) increased 12% year-over-year to $3.55 billion. Its non-GAAP net income grew 14.3% from the year-ago value to $1.35 billion, while its income from operations stood at $1.07 billion, up 5.2% year-over-year. The company's non-GAAP net income per share came in at $11.56, representing a 12.9% year-over-year growth.
The consensus revenue estimate of $3.66 billion for the fiscal third quarter (ending September 2024) represents an 8.7% improvement year-over-year. The consensus EPS estimate of $11.76 for the ongoing quarter represents a 1.5% increase from the same period last year. The company has a promising earnings surprise history, as it surpassed the consensus EPS estimates in three of the trailing four quarters.
Shares of REGN have gained 38.1% over the past year and 29.7% year-to-date.
It is no surprise that REGN has an overall rating of A, equating to a Strong Buy in our POWR Ratings system. It has a B grade for Value and Quality. Out of 335 stocks in the same industry, it is ranked #8.
In addition to the POWR Rating grades I've just highlighted, you can see REGN's Growth, Momentum, Stability, and Sentiment ratings <a href="https://stocknews.com/stock/REGN/">here</a>.
What To Do Next?
Get your hands on this special report with 3 low priced companies with tremendous upside potential even in today's volatile markets:
<a href="https://report.stocknews.com/free-report/3stocks/?formplacement=artbotad_3s">3 Stocks to DOUBLE This Year &gt;</a>

<hr />
REGN shares were unchanged in premarket trading Thursday. Year-to-date, REGN has gained 29.66%, versus a 18.86% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Shweta Kumari</h2> <img src='https:/wp-content/uploads/2022/03/Shweta-Kumari_Image-2.jpg' style="float:left; padding:5px;width:125px;">Shweta's profound interest in financial research and quantitative analysis led her to pursue a career as an investment analyst. She uses her knowledge to help retail investors make educated investment decisions.<a href="https://stocknews.com/authors/?author=shweta-kumari">More...</a>The post <a href=https://stocknews.com/news/regn-alny-ilmn-3-genomics-stocks-transforming-healthcare/>3 Genomics Stocks Transforming Healthcare</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Genomics Stocks Transforming Healthcare

Stock Picks From Seeking Alpha's September 2024 New Analysts

Regeneron co-founder warns of harms from weight-loss drugs: FT

Kymera's Protein Degradation Technology: A Promising Bet For Long-Term Biotech Investors

Regeneron sees IPR&D impact of about $0.43/share on Q3 income

Kiniksa Pharmaceuticals: Looking In On A Developing Growth Story

Baird Q3 2024 International And Global Growth Fund Commentary

Weight-loss drugs: How much should investors worry about side effects?

In a report released today, Terence Flynn from Morgan Stanley maintained a Buy rating on Regeneron (REGN – Research Report), with a price target of...

Morgan Stanley Keeps Their Buy Rating on Regeneron (REGN)

ADYEY

ADYYF

ALNY

AMZN

APTV

ASML

ASMLF

BABA

BABAF

BEIGF

BEKE

BGNE

BIOA

BKRKF

BKRKY

BRENF

CRWD

CUKPF

EVGGF

EVVTY

FROG

GMAB

GNMSF

GOOG

GOOGL

GRAL

ILMN

INMD

INTC

KNSA

KYMR

LEGN

MDALF

NONOF

NVDA

OLPX

PILBF

PPRUF

PPRUY

PROSF

PROSY

RCRRF

RCRUY

RHHBY

RIOCF

RYAAY

RYAOF

SCHW

SNYNF

SOUN

SOUNW

SZKMF

SZKMY

TDBCP

TDBKF

TDOMF

TDOPF

TEAM

TNTTF

TSLA

TSMWF

WXIBF

WXXWY

Screenshot 2024-09-10 at 8.49.39 PM

MAIA

MAIA Biotechnology&#39;s Phase 2 Study Of THIO In Non-Small Cell Lung Cancer Shows Positive Interim Survival Benefits

MAIA Biotechnology's Phase 2 Study Of THIO In Non-Small Cell Lung Cancer Shows Positive Interim Survival Benefits

Press Releases

Dupixent® (dupilumab) Approved in the U.S. as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Eosinophilic Esophagitis (EoE) in Children as Young as 1 Year Old

Press Release: Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old

Small Cap

Opinion

Optimism Grows in the Fight Against Cancer as Breakthroughs and Funding Increase

Regeneron to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on October 31, 2024

Press Release: Dupixent approved in China as the first-ever biologic medicine for patients with COPD

Dupixent® (dupilumab) Approved in China as the First-ever Biologic Medicine for Patients with Chronic Obstructive Pulmonary Disease (COPD)

Press Release: Dupixent approved in the US as the first-ever biologic medicine for patients with COPD

Dupixent® (dupilumab) Approved in the U.S. as the First-ever Biologic Medicine for Patients with COPD

Comments

Regeneron Pharmaceuticals

Actualités

Dernières nouvelles pour Regeneron Pharmaceuticals (NASDAQ:REGN) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL